INT MEDICAL to Invest $10 Million for Additional 0.79% Stake in Dejin Medical

INT MEDICAL (HKEX: 01501) has announced a new agreement to acquire a further stake in Valgen Holding Corporation.

On June 25, 2026, the company, acting as the buyer, entered into an additional share transfer agreement with certain existing shareholders of the target company.

The agreement involves the purchase of 119,545 Series B preferred shares, representing approximately 0.79% of Valgen's total issued share capital, for a total consideration of $10 million.

Valgen Holding Corporation is a holding company with no substantive business operations and holds a 100% equity interest in Dejin Medical.

Dejin Medical is primarily engaged in the research, development, production, and sale of interventional technologies and products for atrioventricular valve diseases, with a focus on mitral and tricuspid valve interventions.

Dejin Medical serves as the main operating entity of the target group within China.

Four products independently developed by the target group have been included in the National Medical Products Administration's special review program for innovative medical devices.

These products are the MitralStitch® transapical mitral valve repair system, the DragonFly™ transcatheter mitral valve clip system, the DragonFly-T® transcatheter tricuspid valve clip system, and the DragonFire® transcatheter myocardial radiofrequency ablation system.

Notably, the DragonFly™ transcatheter mitral valve clip system is the first domestically produced transcatheter mitral valve product approved by the NMPA.

Upon completion of both the initial acquisition and this secondary transaction, the company will hold a combined stake of approximately 23.97% in the target company's total issued share capital.

The board of directors believes that acquiring equity in the target company provides an opportunity to supplement the group's product pipeline in the structural heart disease field.

This move aims to achieve more comprehensive product coverage in this sector and enhance the group's overall competitiveness and long-term development potential in the cardiovascular intervention field.

The secondary acquisition is intended to implement the company's strategy of gradually increasing its shareholding in the target company.